Old drug, new hope: ATRA combo targets tough pancreatic cancer
NCT ID NCT04241276
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase IIb trial tests whether adding ATRA (a vitamin A derivative) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with locally advanced pancreatic cancer live longer without their cancer growing. About 170 participants will receive either the combo or standard chemo. The main goal is to see if the new mix delays tumor progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATRA (tretinoin) plus gemcitabine and nab-paclitaxel
- What this could lead to
- If successful, this could offer a new treatment option that slows the growth of locally advanced pancreatic cancer.
- What could go wrong
- This is a mid-stage trial with 170 people, so results are not yet proven. The drug combination may not work better than standard chemo and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts NHS Trust
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new drug combo shrink Hard-to-Treat tumors?